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Abstract
We report a case of ocular myasthenia gravis (MG)
accompanied by anosmia. A 76-year-old man had
idiopathic anosmia of 2-year duration. Four months
before consultation, he began to have drooping in
the right upper eyelid along with muscle soreness,
distension, and pain in the nape. His tongue was
dark-red with a thin and white coating; his pulse
was wiry and slippery. According to Traditional Chi-
nese Medicine, eyelid drooping and anosmia are
the main signs of liver constraint and spleen defi-
ciency. In Western Medicine, the diagnosis was ocu-
lar MG and idiopathic anosmia. Our patient, along
with the literature, suggests that anosmia may be
an early symptom before MG. MG accompanied by
anosmia could be a special subtype of MG accord-
ing to antibody production and symptoms.
© 2016 JTCM.
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INTRODUCTION
We report a case of ocular myasthenia gravis (MG) in
an elderly gentleman. Before the initial consultation,
he had suffered from loss of olfaction (anosmia) for 2
years as well as flaccidity and drooping in the right up-
per eyelid for 4 months.
After hospitalization, he was diagnosed with a droop-
ing eyelid and anosmia in terms of Traditional Chinese
Medicine (TCM), and as having ocular MG with anos-
mia in terms of Western Medicine. Analyses of the
pathologic evidence suggested that the olfactory disor-
der could be manifestation of MG. We speculate that
MG accompanied by anosmia is a special subtype of
MG.
CASE REPORT
The patient was a 76-year-old man. He complained of
anosmia of 2-year duration, and flaccidity and droop-
ing of the right upper eyelid for 4 months, and was
hospitalized on 22 November 2012. He had developed
anosmia with no obvious predisposing factor in 2010
and received no treatment. In July 2012, he went fish-
ing and suddenly felt weak and found that his right
upper eyelid was drooping, but he did not seek medi-
cal attention. The condition worsened gradually, and
he tended to feel better in the morning than in the
evening.
In August 2012, his vision was blocked partially by the
drooping eyelid and his nape felt sore and painful. He
sought help from our hospital. No abnormalities were
founduponCTof the chest and he refusedmedications.
On 22 November 2012, his symptoms worsened and
he was admitted to the Department of Encephalopathy
of our hospital. His manifestations were anosmia, a
drooping right upper eyelid, muscle soreness, and dis-
tension and pain in the nape. Diplopia, indifferent fa-
cial expressions, drooling, weakness in rotation of the
neck, dyspnea, or weakness in the extremities were not
observed.
He had a history of scrofula that had resolved. He had
been diagnosed with coronary disease, but had never
taken any medications for it. He did not smoke but
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consumed a small amount of alcohol. His father had a
history of eyelid drooping from at the age of 90
years, but no diagnosis had been made or treatment
administered.
Clinical examination revealed: anosmia; drooping of the
right upper eyelid: fissure in the right eyelid of 6 mm;
fissure in the left eyelid of 10 mm; flexible movement
of the eyeballs; pupil diameter (both sides) of 2.5 mm;
both pupils sensitive to direct and indirect light reflex.
The tongue and uvula protruded on the midline. Dip-
lopia or forceful closing of the eyes was not identified.
Breathing movement was symmetric on both sides,
and muscle strength in the four extremities was grade
5. Volume and tone of muscle were normal. Tendon re-
flexes of the four extremities were symmetric, bilateral
Babinski sign (and its equivalent signs) were negative,
superficial and deep sensations of the trunk and four
extremities were symmetric, and the ataxia test was neg-
ative. His tongue was dark red with a thin, white coat-
ing. His pulse was wiry and slippery.
On 27 November 2014, a fatigue test of the upper eye-
lids showed an initial fatigue time for the right upper
eyelid to be 32 s (score, 1) whereas that of the left up-
per eyelid was > 60 s (score, 0). The neostigmine meth-
ylsulfate test showed a grade of ≥ 60%.
On 29 August 2012, routine and contrast-enhanced
CT of the chest showed an old lesion in the right up-
per lung, as well as interstitial changes in the right low-
er lung. On 23 November 2012, MRI of the head
showed ischemic infarction in bilateral frontal and pari-
etal lobes, basal ganglia, and around the lateral ventri-
cle; senile encephalic changes and minor inflammation
of the ethmoid sinus were also observed.
On 29 November 2012, routine CT with three-dimen-
sional reconstruction of paranasal sinuses showed local
thickened mucus in the maxillary sinus and a bulging
inferior nasal concha. Physicians from our ENT De-
partment carried out nasal endoscopy, which showed
mild congestion of nasal passages, no obvious swelling,
and no neoplasm in the nasal septum or olfactory cleft.
The patient refused an electrophysiology test. Caus-
ative factors of anosmia remained unknown. On 25
December, 2012, a serum test was positive for antibod-
ies against titin, ryanodine receptors, and muscle-specif-
ic tyrosine kinase (MuSK), but negative for acetylcho-
line receptors and acetylcholine.
In terms of TCM, the diagnosis was a drooping eyelid
and anosmia with a symptom pattern of liver con-
straint and spleen deficiency. In terms of Western Med-
icine, the diagnosis was ocular MG and idiopathic an-
osmia.
During hospitalization, the patient refused to take hor-
mone and pyridostigmine therapies. Only cobamamide
was administered to nourish the nerves. The TCM regi-
men was based on soothing the liver, strengthening the
spleen, boosting Qi, and lifting Yang.
The patient was discharged on 30 December 2012
with an improved right upper eyelid. On 27 Septem-
ber 2014, he informed us by telephone that there was
no improvement in olfaction. Since June 2014, his left
eyelid began to feel weak and a drooping eyelid had de-
veloped. Currently, he is taking pyridostigmine tablets
(30 mg, t.i.d.) and his condition is under control.
DISCUSSION
Pathogenesis of MG
MG is an acquired autoimmune disease that occurs
mainly due to a defect/absence of nicotinic acetylcho-
line receptors at the post-synaptic neuromuscular junc-
tion. MG involves antibody-mediated destruction of
acetylcholine receptors, is dependent on cell immunity,
and is associated with complement. Causative factors
include autoimmunity, passive immunity, and drug
use. The typical clinical manifestation is fluctuating
weakness and fatigue of certain groups of striated mus-
cles (mostly extraocular muscles), a condition that is
much milder in the morning and more severe in the
evening, and which is aggravated by exertion and remit-
ted by rest. The most common initial symptom is
asymmetric ptosis and / or bilateral diplopia due to
weakness of extraocular muscles.
According to the Osserman classification, MG can be
categorized into five types. In type 1, only extraocular
muscles are affected and no other muscle groups are in-
volved within 2 years of the diagnosis. In type 2, mild,
generalized MG involving at least one muscle group is
observed. Type 3 is characterized by severe, generalized
MG that occurs and progresses drastically, and respira-
tory muscles are often involved within 6 months of the
diagnosis. In type 4, delayed, severe, generalized MG
occurs in an insidious and gradual fashion, and respira-
tory muscles are involved within 2 years of the diagno-
sis. In type 5, skeletomuscular atrophy is noted within
6 months of the diagnosis.1
Recent studies have shown that multiple antibodies
take part in MG, among which the mechanism of ac-
tion of antibodies against acetylcholine receptors is rela-
tively well characterized.2
Antibodies against titin are present in MG patients
with antibodies against acetylcholine receptors, and
suggest MG accompanied by a thymoma (MGT).3,4
The possibility of a thymoma cannot be excluded even
if a MG patient does not have antibodies against titin.5
Studies have shown that MGT is associated with MG
severity.6,7
Antibodies against MuSK are usually present in the se-
rum of MG patients who do not have antibodies
against acetylcholine receptors.8 Its relevance is related
to test methods, patient ethnicity9-14 and MG type.15,16
This type of MG occurs acutely and often involves the
respiratory muscles.17 It responds poorly to cholinester-
ase inhibitors and removal of the thymus gland.18,19 A
possible mechanism of action is that antibodies against
MuSK influence accumulation of acetylcholine recep-
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tors by blocking the combination of MuSK and
low-density lipoprotein receptor-related protein (LRP)
4.20
Antibodies against ryanodine receptors influence mus-
cle contraction by inhibiting opening of ryanodine re-
ceptor channels and calcium release. Studies suggest
that having antibodies against ryanodine receptors is re-
lated to MGT and manifests mainly as delayed, severe
MG.21,22 MGT may render weakness due to damage to
excitation-contraction coupling.23
Having antibodies against LRP4 can cause muscular
weakness: they can damage the structure of the neuro-
muscular junction and disturb the combination of
agrin and LRP4 to influence accumulation of acetyl-
choline receptors.24,25 Antibodies against Kvl4 mainly af-
fect voltage-activated potassium channels on the sur-
face of muscle fibers, thereby influencing membrane re-
polarization and maintenance of the resting potential.23
Antibodies against acetylcholine are often present in
MG patients who do not have antibodies against acetyl-
choline receptors and who have a poor reaction to the
prostigmine test. A combination of antibody and syn-
aptic acetylcholine inactivates acetylcholine and hin-
ders its hydrolysis. Then, acetylcholine acts on
post-synaptic membranes to depolarize them, thereby
influencing subsequent nerve transmission.26
Presynaptic membrane antibody can indicate damage
to presynaptic membranes and is strongly associated
with having antibodies against acetylcholine receptors.27
Some studies have shown matrix metalloproteinases28
to be associated with MG. Mitochondrial dysfunction
has also been associated with MG.29,30 An important fac-
tor in neuromuscular diseases is mitochondrial dysfunc-
tion, which can result in energy deficiency.31
Anosmia and diseases of the nervous system
The olfactory system comprises the olfactory epitheli-
um, olfactory nerves, olfactory bulb, olfactory tract,
and connections to the nervous system. According to
severity and characteristics, olfactory disorders can be
classified into anosmia, hyposmia, hyperosmia, paros-
mia and olfactory hallucination.
Anosmia refers to no reaction to olfactory stimulation
and can be subdivided into entire, part and special
types.32 Uniform diagnostic methods and standards for
measurement of olfactory dysfunction are lacking.
Commonly used methods are subjective olfactory tests,
objective olfactory tests, and radionuclide imaging.33
The cause of olfactory disorders are peripheral damage
(blockage of the nasal cavity and injured olfactory mu-
cus cells) and central damage (disorder of the cerebral
cells responsible for sensing odors).
Several factors can lead to olfactory disorders. Com-
mon factors are infection of the upper respiratory tract,
aging, nasal diseases, brain trauma, smoking, diabetes
mellitus, depression, hearing disorders, epilepsy and
drug use. Olfactory disorders can also be part of diseas-
es of the nervous system such as Alzheimer's disease
(AD), Lewy body dementia (LBD), schizophrenia, mul-
tiple sclerosis, and Parkinson's disease (PD).34 Studies
have shown that anosmia or hyposmia is a main symp-
tom of AD, LBD and PD.
Olfactory disorders in AD are associated with pigment
formation in the central nervous system and neuronal
degeneration. The pathogenesis involves loss of olfacto-
ry functions, alteration of olfactory nervous pathways,
as well as morphologic and changes in concentrations
of neurotransmitters.35 The latter include changes in
levels of acetylcholine,36 noradrenaline,37 dopamine,38 as
well as the transporters and receptors of 5-hydroxytryp-
tamine.39,40
LBD has similar clinical characteristics and pathologic
changes to those seen in PD, including anosmia.41
Olfactory dysfunction among PD patients is related to
genetics, proteins, the environment, and changes in
neurotransmitter levels.42 Studies have shown that
changes in levels of acetylcholine, noradrenaline, dopa-
mine, 5-hydroxytryptamine and other neurotransmit-
ters may be involved in the olfactory dysfunction seen
in PD.43 In particular, cholinergic denervation of ar-
chicortex is a strong factor for olfactory dysfunction in
PD.44
A common feature of olfactory dysfunction in AD and
PD is cholinergic damage. Olfactory dysfunction oc-
curs in AD and PD before the onset of motor or ner-
vous symptoms. Therefore, olfactory examination can
help to screen and diagnose AD and PD at an early
stage.
Etiology and pathogenesis of anosmia and the
"wilting symptom pattern" (WSP) in TCM
In TCM, MG is termed the WSP or "drooping eyelid"
if it manifests mainly as blepharoptosis. The WSP is re-
lated to invasion by exogenous pathogens and dysfunc-
tion of the lungs, spleen, liver and kidneys. The com-
mon syndromes of MG and its therapies and herbal
formulas are clear.45-47 Studies have shown that TCM
can be efficacious against WSP.47 Progress has been
made in treating MG by TCM. For example, using
TCM, a functional relationship between the spleen
and mitochondria,48 the intervention effect of TCM on
antibodies against acetylcholine receptors,49 and regula-
tory functions in the immune system50 have been illus-
trated.
In TCM, olfactory dysfunction is in the scope of "loss
of olfaction". TCM theory holds that the nose has
abundant blood and vessels. Though it is an opening
to the lungs, it can be attributed to the earth due to its
external location. Thus, it has a close relationship to
the lungs and spleen. The heart, liver and kidneys can
also influence olfaction.
The lungs govern Qi, control respiration, and have an
opening to the nose. If exogenous pathogens attack the
lungs and the lungs fail to distribute fluids, then the in-
ternal organs, four extremities, tendons and vessels will
lack nourishment, possibly leading to the WSP. Lung
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Qi stagnation in the nose results in loss of olfaction.
The spleen governs the muscles and is the source of
generation of Qi and blood. Sufficient spleen Qi en-
sures abundant Qi, abundant blood, and strong mus-
cles. However, weakness of spleen Qi will prevent it
from transporting and transforming water and food to
produce nutrients for all parts of the body. Weakness
and the WSP will occur if Qi and blood are not suffi-
cient and muscles are not nourished. Lack of nourish-
ment in the nose will lead to anosmia. The liver stores
blood, opens into the eyes and is associated with ten-
dons. Constraints in liver Qi, deficiency of liver blood,
and malnourishment of tendons and vessels will result
in weakness and wilting of the body. Disorder of Qi
movement can cause inhibited opening of the nasal cav-
ity. The kidneys govern the bone, produce bone mar-
row, and store primordial Yin and Yang. Insufficient in-
nate endowment, prolonged illness or aging can con-
tribute to deficiency of kidney essence, Yin and Yang.
If the kidneys fail to nourish tendons, bones and mus-
cles, weakness and the WSP will occur; if they fail to
warm nasal orifices, anosmia will develop.
Therefore, in terms of TCM, the WSP and anosmia
have similar etiologies and pathogenesis, which can
make them occur simultaneously.
Case characteristics
Or patient did not have a history of acute infection of
the upper respiratory tract, smoking, external trauma
to the head, chronic sinusitis, or migraine. He was diag-
nosed with coronary disease, but he was not treated for
it. Contrast-enhanced CT of the chest did not reveal a
thymoma. CT of paranasal sinuses and consultations
in the ENT Department showed that anosmia was not
caused by sinusitis.51 Mini-mental state examination
did not show reduced cognitive function. Two years af-
ter anosmia, the right side of the upper eyelid started
to droop. At 2-year follow-up, drooping of the left eye-
lid was noted, but other muscle groups were not in-
volved. Serum profiles and pharmacologic features sug-
gested a diagnosis of ocular MG.1 Also, he was in good
health with no other diseases of the nervous system,
such as PD, AD, or cerebral infarction.
Three points of this case are noteworthy. First, no oth-
er pathologic factors except for old age could have
caused olfactory dysfunction. However, old age is not
essential for the onset of olfactory dysfunction, so the
reason for olfactory dysfunction in this case is unclear.
Second, studies suggest that having antibodies against
titin, ryanodine receptors, and MuSK, but not for ace-
tylcholine receptors or acetylcholine, suggest MGT
and severe MG.21 However, contrast-enhanced CT of
the chest did not reveal a thymoma. Also, only ocular
muscles were involved and the patient was in a stable
condition. These findings are not in accordance with
the literature. Finally, authors have reported that anti-
bodies against titin are present in MG patients with an-
tibodies against acetylcholine receptors, and that no an-
tibodies against titin are found in MG patients with an-
tibodies against MuSK or no antibodies against se-
rum.19 However, our patient had antibodies against ti-
tin and MuSK, which merits further study.
Leon-sarmiento et al 52 carried out a test for odor identi-
fication for 27 MG patients, 27 healthy volunteers,
and 11 patients with polymyositis. MG patients were
found to be significantly worse at identifying odors
than the other two groups. Only ≈15% of MG pa-
tients had olfactory dysfunction before the test. That
study suggested MG patients have olfactory dysfunc-
tion and that it may be associated with cholinergic
damage to the central nervous system.52
CONCLUSIONS
On the basis of our case study and the literature, we
propose two hypotheses. First, though our patient did
not have antibodies against acetylcholine receptors and
acetylcholine, we cannot exclude the possibility of de-
tecting low affinity of acetylcholine receptors by
non-standard methods.53 Moreover, antibodies against
MuSK can also inhibit aggregation of acetylcholine re-
ceptors. Anosmia in our patient could have been an ear-
ly symptom before other MG manifestations. Second,
MG accompanied by anosmia could be a new subtype
according to antibody production and symptoms.
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